Gapping down
In reaction to disappointing earnings/guidance: CPXX -1.5%
M&A news: AFFX -6.5% (says reviewing offer from Origin Technologies, continues to recommend stockholders vote for the pending acquisition by Thermo Fisher Scientific (TMO)), MAR -0.7% (Starwood Hotels (HOT) and Marriott (MAR) revise merger)
Select oil/gas related names showing early weakness: SDRL -4.3%, RIG-2.3%, WLL -2%, MRO -2%, TOT -1.7%, BP -1.4%, RDS.A -1.3%
Other news: JMP -31.6% (confirms that it met with representatives of the FDA in a Pre-IND meeting concerning JNP-0101), BPMC -5.6% (enters into collaboration & license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche), BMRN -4.3% (reports phase 3 study results), CETV-2.3% (still checking)
Analyst comments: SALT -5.4% (downgraded to Hold from Buy at Evercore ISI), NGD -5.2% (downgraded to Sector Perform at RBC Capital Mkts), VRX-4.5% (downgraded to Equal Weight from Overweight at Barclays, to Underperform at Mizuho), X -3.9% (downgraded to Underperform from Hold at Jefferies), AV -2.4% (downgraded to Market Perform from Outperform at Bernstein ), CPRT -2.2% (downgraded to Neutral from Buy at BofA/Merrill ),INTC -1.5% (downgraded to Underperform from Mkt Perform at Bernstein),NTAP -1% (downgraded to Underperform from Neutral at Macquarie ), FISV-1% (downgraded to Perform from Outperform at Oppenheimer)
In reaction to disappointing earnings/guidance: CPXX -1.5%
M&A news: AFFX -6.5% (says reviewing offer from Origin Technologies, continues to recommend stockholders vote for the pending acquisition by Thermo Fisher Scientific (TMO)), MAR -0.7% (Starwood Hotels (HOT) and Marriott (MAR) revise merger)
Select oil/gas related names showing early weakness: SDRL -4.3%, RIG-2.3%, WLL -2%, MRO -2%, TOT -1.7%, BP -1.4%, RDS.A -1.3%
Other news: JMP -31.6% (confirms that it met with representatives of the FDA in a Pre-IND meeting concerning JNP-0101), BPMC -5.6% (enters into collaboration & license agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche), BMRN -4.3% (reports phase 3 study results), CETV-2.3% (still checking)
Analyst comments: SALT -5.4% (downgraded to Hold from Buy at Evercore ISI), NGD -5.2% (downgraded to Sector Perform at RBC Capital Mkts), VRX-4.5% (downgraded to Equal Weight from Overweight at Barclays, to Underperform at Mizuho), X -3.9% (downgraded to Underperform from Hold at Jefferies), AV -2.4% (downgraded to Market Perform from Outperform at Bernstein ), CPRT -2.2% (downgraded to Neutral from Buy at BofA/Merrill ),INTC -1.5% (downgraded to Underperform from Mkt Perform at Bernstein),NTAP -1% (downgraded to Underperform from Neutral at Macquarie ), FISV-1% (downgraded to Perform from Outperform at Oppenheimer)